Roles
- Assistant Professor of Clinical Medicine
-
Biography
Michele Dana Henner Stanchina, D.O., M.S. is an Assistant Professor of Clinical Medicine in the Division of Hematology at the University of Miami Miller School of Medicine. She completed her Hematology-Oncology fellowship at Jackson Memorial Hospital/University of Miami and is board-certified in hematology and oncology, specializing in hematologic malignancies with a focus on lymphoma.
Originally from New York, Dr. Stanchina earned her undergraduate degree from Skidmore College. She worked as a Clinical Research Coordinator for five years before earning a Master’s in Neuroscience at Tulane University. She completed her medical degree at NYIT College of Osteopathic Medicine and her Internal Medicine residency at the Icahn School of Medicine at Mount Sinai West-Morningside (St. Luke’s-Roosevelt) prior to her fellowship in Miami.
Dr. Stanchina’s clinical expertise includes the diagnosis and management of lymphoma and other hematologic malignancies, and she is actively involved in clinical research which focuses on novel therapies and treatment strategies for these diseases. Her work aims to improve patient outcomes through translational research that bridges laboratory discoveries with clinical application. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 3 clinical trials.
-
This study is being done to answer the following question: How does treatment with mosunetuzumab compare to rituximab for lengthening the time that you live with Nodular lymphocyte-predominant Hodgkin lymphoma without it getting worse? We are doing this study because we want to find out if this approach is better or worse than the usual approach for Nodular lymphocyte-predominant Hodgkin lymphoma. The usual approach is defined as care most people get for Nodular lymphocyte-predominant Hodgkin lymphoma.
- Principal Investigator: Michele Stanchina
- Study Phase: Phase II
- Enrollment Status: Open
-
To compare the 3-year milestone progression free survival (PFS) probabilities in participants with previously untreated, low tumor burden follicular lymphoma randomized to the rituximab arm versus the mosunetuzumab arm.
- Principal Investigator: Michele Stanchina
- Study Phase: Phase III
- Enrollment Status: Open
-
To determine the 1-year PFS rate of patients with Stage IIB-IV HL treated with 4 cycles of BrECADD CIT.
- Principal Investigator: Michele Stanchina
- Study Phase: Phase II
- Enrollment Status: Open
